The Genome Institute of Singapore is a unique place for scientific discovery. We believe that a future in biology lies in the fusion of highly comprehensive and massively parallel genomic and computational approaches with cell and medical biology. Therefore, we seek the integration of technology and biology towards answering questions of medical importance. The Agency for Science and Technology Research (A*STAR) is the parent funding body for the GIS Our ApprOAch And Our Science Our scientific focus is to investigate questions in the realm of functional genomics and integrative biology. We exploit the intersect between genomics, cell biology, and medicine and take advantage of the contrasting genetic history of Pan-Asian populations to uncover fundamental truths. Our biological focuses on cancer biology, stem cell genomics, cellular pharmacology, and host-pathogen interactions are integrated with technology development in order to create novel solutions to difficult problems.
and has a long term commitment to create a world-class infrastructure.
In October 2003, we inaugurated our new research building, the Genome -a 7,200 sq meter advanced facility. Set in the Biopolis -a 180 hectare biomedical city within the Buona Vista Science Hub, the Genome is adjacent to other biomedical institutes such as Singapore's Institute of Molecular and Cell Biology, the Bioinformatics Institute, the Institute of Bioengineering and Nanotechnology, the Biotechnology Institute, the Biomedical Research Council, regional and multinational industrial R&D organisations.
The Biopolis provides an excellent environment conducive to the exchange of knowledge and collegial interactions. It was planned as a complete community that supports living, working, learning and playing: combining state-of-art research infrastructure with entertainment and educational facilities.
In mid 2008, the engineering research institutes were relocated to newly-constructed facilities called Fusionopolis, also within the Buona Vista Science Hub. Together, the biomedical and engineering research arms of A*STAR form an integral part of excellence in scientific research.
GIS houses over 300 scientists, trainees and staff. The major technical platforms of high throughput sequencing, molecular cytogenetics, bioinformatics, single cell genomics, high throughput/ content screening and genome engineering have been integrated with programmes in molecular and cellular biology, computational biology and human genetics.
With these components in place, GIS is well positioned for success.
Consistent with our remit as a national resource, we provide the genomic infrastructure for Singapore and train new talent in this emerging field.
As the nucleating force for collaborative genomic studies in Singapore, the GIS seeks to unite Singaporean scientists around collective projects of significance and extend this partnership internationally in both the academic and commercial sectors.
BaCkGrOuND CulTurE
Our focus on systems and integrative biology requires an organisational structure and social culture that encourages collective effort, and iterative experimentation between the wet laboratory and computational modeling.
For these reasons, we have spent a great deal of energy in crafting the cultural state of our institute which prizes flexibility, individual intensity and collective impact. The Genome Institute of Singapore specifically recognises technology-focused scientists to be as important as biology-centric investigators, and we encourage technology experts to team with biologists to address fundamental biological questions.
Our scientific leadership structure reflects our diverse capabilities and our efforts to nurture early talent. We have principal investigators that range in expertise from basic biology to translational and medical fields. Our platform leaders handle the latest in technology and comprise some of our early career researchers (Next Generation Sequencing, High-throughput Biology, Genome Engineering, Genotyping, Cytogenetics, Single Cell Genomics).
We have a cohort of exceptional young scientists in our GIS fellows programme who are driving their own research projects that integrate into the larger GIS picture. Together we believe the best ideas can be harnessed and pursued. Of the 1,175 personnel who were determined to be at risk across these camps, 1,100 received oseltamivir (Tamiflu) prophylaxis. The result was stunning -the infection rate dropped from 6.4 percent before intervention, to 0.6 percent after intervention. The sequencing effort by the GIS was able to show the direct transmission process of these viruses, and thus confirm that these outbreaks were restricted to viruses caught at the army camp, the first time that this technique has been possible.
GiS-SpOnSOred eVenTS

BHC-NTU-GIS Joint Seminar
The Over the past nine years, the stem cell group at GIS has comprehensively assessed genes required for stem cell function, and helped to define the specific functions of these genes through cutting-edge genetic technologies, such as genome-wide sequencing. These efforts have led to the discovery and definition of novel regulatory factors required for the functions of embryonic stem (eS) and other stem cells. Based on the Paired end diTags (PeT) strategy, the team devised Gene Identification Signature (GIS) analysis to precisely demarcate the boundaries of gene coding regions and invented the ChIP-PeT (chromatin immunoprecipitation coupled with paired-end ditagging) analysis for highly accurate, robust and unbiased genome-wide identification of transcription factor binding sites in the genome. With the newly developed multiplex sequencing (MS-PeT) method, the PeT sequencing strategy can achieve over 100-fold efficiency improvement. The team also developed total computational solutions to accommodate and process the high volume of data generated. Collectively, they established an integrated, high throughput and high precision technology platform for the comprehensive characterisation of the human genome and transcriptome.
The team has numerous publications on their invention and exciting biological discoveries in prestigious journals. They were also awarded a uSD $1-million grant by nIH to further develop their technology.
NUS Centennial Genesis Award 2005
Dr Bernard Leong, Research Scientist, Information and Mathematical Sciences
Returning A*STAR scholar and GIS scientist Bernard leong won the nuS Centennial Genesis Award for his entrepreneurship efforts in starting up a biotech company, SimuGen, specialising in gene profiling and computational biology. The company has produced a kit that will predict liver heptatoxicity cheaply, accurately and efficiently. rESEarCH ParTNErS empOwerinG reSeArch We are at the onset of a revolution in genomics-based health and life sciences. Advances in genomic technologies, genetic engineering, computational biology, disease model systems, and molecular cell biology are generating discoveries with remarkable speed that are leading us to novel and precise therapies for human diseases. Therapies from population studies designed for the impersonal average patient are going to be replaced by individualised care, tailored to the individual's genetic and biochemical makeup -a new paradigm in personalised medicine. To make this promise a reality, we must advance from a focus on single gene effects to understanding and controlling the complex interactions throughout the networks of all genes involved in health and disease contexts. New innovations in the genomics space put mastery of biological complexity within our reach. With creative use of such new technologies and tools, we can devise definitive solutions to complex medical problems and develop a truly translational biomedical approach.
To do this, the Genome Institute of Singapore innovates by sharing knowledge, risks and successes, and we innovate across boundaries. We have deep experiences in identifying the right opportunities in biomedical sciences and also have the relationship-building skills to work collaboratively with our partners. Recognised as a leader in genomic research to partner with, we have a strong desire to deliver future success for our partners and for our institute.
It is our collaborative approach that leads to scientific and commercial success. Partnering with GIS means that our partners gain from our capabilities: executive leadership, strategic alliances and knowledge management, deal flexibility, research and development, translational biosciences like stratified oncology and (companion) diagnostics.
The focus of each of our alliances is on how we can create a sustainable win-win situation for all partners involved; our partners play an active role in the scientific and commercial development -we consider a variety of deal types that range from Research Collaboration Agreements (RCA), Project or Service Agreements (PA), Licensing (LA), Joint Labs and Centres of Excellence (CoE).
Service Agreements, for instance, allow delivering results to a partner when a project is straightforward and does not include significant novel research. This might be a sequencing project, karyotyping agreement, data or genome analytics project or consultancy.
In a Research Collaboration Agreement, the institute will perform research and development together with our partners and the outcome will be new Intellectual Property (IP) and know-how that addresses our partners' questions and problem statements. Such a project will enhance the partner's technology edge and could result in a downstream Licensing Agreement.
At the Genome Institute of Singapore we believe in providing an environment where innovation can flourish.
In the setup of a Joint Lab or Centre of Excellence, GIS engages with partners on a long-term strategic basis. Dedicated GIS resources become accessible to our partners and vice versa to advance research, technology transfer and capability building for our partners.
Once a partnership is established, we have a Strategic Alliances and Knowledge Management department that is focused on cultivating a strong relationship throughout the partnership. The group assists with identifying lines of communication and in establishing a governance structure.
ALLiAnceS wiTh induSTry Industrial Partnerships
Making an impact on the world around us is an important focus at the GIS. Through research collaborations with the industry, we seek to understand and solve complex application related questions in the genomics area.
The GIS is open to requests from the industry and our business development team works to facilitate project management and coordination with our research groups. Successful collaborations with many of the world's leading pharmaceutical, diagnostic and biotech companies have been carried out at the GIS, to the extend that we have built a strong repute in the biotech and pharma environment. Studies have, for instance, covered areas like application developments, genomic studies, molecular diagnostic development, visualisation of complex genomics data, and biomarker discovery or evaluations.
Together with one of the top 10 pharmaceutical companies, researchers at the GIS studied the Using our certified molecular diagnostics laboratories and expertise in assay development and validation, a recent product prototype was developed to stratify patients with Chronic Myelogenous Leukemia (CML) for the best available treatment.
In addition to the more strategic research collaborations, the teams at the GIS also offer consultancy and expert advice in the research focus areas as well as service-based agreements covering sequencing, real time PCR and molecular or companion diagnostics development.
Besides the strong relations GIS has built with the biomedical industry, we establish a strong network with our clinical and academic partners to enhance knowledge exchange, benchto-bedside translation and to make an impact on medical healthcare through genomics, worldwide.
contact our Strategic alliances and knowledge management department for discussion on how the gIS can support your projects at business@gis.a-star.edu.sg GIS strives to build a framework for strategic alliances, entrepreneurship and translating research outputs for public's health together with industry, academia, clinicians and policy stakeholders, and we like to be the preferred partner for research and practice of biomedical innovation. 
SeLecTed ALLiAnceS wiTh Our AcAdemic pArTnerS
HumaN GENETICS
Understanding the genetic basis of human diseases and related physiological traits is the main objective of the programme. Many of the disease phenotypes we focus on are complex diseases whose genetic risk factors are multi-factorial and work in concert with a number of environmental forces. Using both hypothesis-driven investigations and unbiased genome-wide interrogations, we are working towards identifying genomic regions or genes whose natural variations influence disease predisposition, progression and treatment outcomes.
diSeASe Gene diScOVery By building up a common set of high-throughput genotyping and sequencing technologies and statistical methods through collaborative efforts, our investigation of disease inheritance and susceptibility covers diverse disease areas, including cancers (breast cancer, nasopharyngeal carcinoma, non-Hodgkin lymphoma),
I
Senior Investigators LIU Jianjun / Martin HIBBERD Sonia DAVILA / KHOR Chiea Chuen Pauline Crystal NG / Roger FOO ZHAI Weiwei WANG Chaolong neuropsychiatric disorders (Parkinson Disease, schizophrenia), infectious diseases (tuberculosis, leprosy, meningococcal disease, Kawasaki disease and dengue), immunity and inflammation diseases (psoriasis, SLE, ankylosing spondylitis, IgA nephropathy, IBD), and eye diseases (age-related macular degeneration, glaucoma, pseudoexfoliation syndrome, and extreme myopia) and optic traits (central corneal thickness, optic nerve heard parameters, and intraocular pressure).
We have extensive research programmes on interrogating common risk variants by genomewide association study (GWAS) and are increasing our efforts on deciphering the contribution of low frequency and rare genetic variants to human diseases by carrying out targeted or whole exome sequencing analysis of patient cohorts, particularly the ones with either severe phenotypes or strong family inheritance. Availability and affordability of high throughput sequencing have made possible the generation of a plethora of sequencing data in a large collection of patients affected with complex and rare diseases, which will help us to achieve a good understanding on the whole spectrum of diseaserelated genetic variants.
FuncTiOnALiSATiOn OF diSeASe riSk LOci
We are also interested in understanding biological mechanisms that underlie these genetic risk loci by pinpointing causal variants through fine-mapping analysis and characterising their functional impacts using in vitro and in vivo model systems. By combining comprehensive association analysis and functional annotation of all the variants within the critical region of a disease risk locus, we are searching for functional variants that are the primary driver and thus the causal event of disease association. Our effort has also gone beyond regional fine mapping analysis into whole genome interrogation, for example, by analysing all the genetic variants within various transcriptional binding sites in large clinical cohorts of diseases. In addition, banking on the great number of novel disease risk loci discovered by our genetic studies of common and rare diseases, we are collaborating, with other research programmes at the GIS, to pursue the functional investigation of these genetic risk loci by building up in vitro cellular models of disease where genetic risk variants are introduced into disease-relevant cells derived from either embryonic stem cells (ES) or induced pluri-potent stem cells (iPS) for functional interrogation. As a complementary effort, we are also collaborating to establish in vivo model animals for the functional investigation of disease riskassociated genes or genetic variants.
pOpuLATiOn And eVOLuTiOnAry GenOmicS And STATiSTicAL GeneTicS
Since the extent and distribution of disease predisposing genetic variation in the human species today is the result of a long and complicated evolutionary, migratory, and demographic history, we are interested in investigating population and evolutionary processes affecting genetic variations in modern human populations. We have been working on assessing the extent of inter-and intra-population genomic variation and detecting signatures of positive natural selection as well as investigating genomic variation across multiple global and regional populations. In addition, we are also interested in understanding the history of introgression from archaic sister species and their distribution into extant human populations as well as the convergent evolution between domesticated species (e.g. dogs) and human beings. Such population and evolutionary genomic studies provide a unique opportunity to look at disease genetics at a much broader scale.
Furthermore, we are also interested in developing novel statistical methodologies to progress beyond searching for disease association in the genome at individual SNP level, to incorporate regional or gene-based evidences and to pursue pathway analysis. To control for population stratification in disease association studies, we have also been developing methods to provide efficient and accurate ancestry estimation for both sequencing (including target sequencing, exome sequencing, and whole genome sequencing) and array-genotyping data as well as exploring novel strategies to control for population stratification and to boost statistical power for rare variant association studies by integrating information from large amounts of existing genetic data, expression data, and functional annotation data.
INFECTIOuS DISEaSES
GIS has utilised cutting edge genomic technology platforms to investigate infectious diseases from multiple perspectives. By looking at the genomes of both the pathogen and the host, together with their transcriptomic responses, we have enabled a rapid understanding of the host pathogen interaction during infectious diseases.
We aim to decipher the specific effects of variation in the genomes of the host and the pathogen using global networks, both in vivo and in vitro. Our technological capabilities are being applied to patient samples, at large scales, for diagnosis and patient characterisation. These approaches allow us to perform molecular epidemiological studies on a range of disease, from Dengue, Tuberculosis, Urinary tract infections to SARS, avian influenza and a full range of others. Increasingly, this is also allowing us to evaluate the evolution of natural pathogen
isolates, using population diversity to investigate the causes of disease and disease severity. Given our unique position in Southeast Asia, we are also developing the tools and the infrastructure to proactively anticipate trends in disease and resistance as well as to prioritise emerging infectious threats to human health.
The raw genetic data is handled by the Computational and Systems Biology group, who is developing novel analytical approaches for data organisation and analyses that are critical to further deciphering the evolution and epidemiology of infectious diseases. These tools are being utilised across the community to ensure impact.
We also investigate human health, from understanding the genetic basis of a successful vaccine response, to understanding healthy skin and gut biomes. With probiotic dairy products developing into one of the most successful categories of functional foods, we are also investigating how these biomes may be enhanced, with wide applications to other, perhaps unexpected, conditions such as inflammatory and autoimmune diseases and cancer development. The application of genomics technologies to explore stem cell biology has been a pillar of research at the GIS since its inception. Stem cells have the unique and defining characteristics of unlimited self-renewal and the capacity to differentiate into progeny cells of specialised functions. This has spawned heightened interest in using stem cells for a variety of applications STEm CEll aND rEGENEraTIVE BIOlOGY in the field of regenerative medicine. By combining expertise in cell biology, developmental biology, genomics technologies and bioinformatics, we have established a remarkable track record in dissecting the regulatory networks that control stem cell function. Our work has led to fundamental discoveries in how cell fates are specified during normal development and provided key Having gained a firm understanding of how cell fates are controlled, the programme is now capitalising upon this knowledge. Directed differentiation of stem cells now allows us to generate human cells and multicellular tissues in a culture dish. for example, the teams are now growing human neurons, liver cells, and heart cells from both healthy individuals as well as patients who are afflicted with debilitating genetic diseases. This line of research is yielding a trove of information about the molecular basis of many diseases, which we are translating into novel diagnostics and therapeutics through partnerships with clinicians and pharmaceutical companies. The programme is also taking advantage of new genome editing technologies to introduce and repair genetic variations in stem cells and their differentiated progeny to study the function of these genes in biology and disease. 4. To rapidly evolve TIC-specific treatment modalities into clinical trials. Hit compounds are taken through validation, in vivo toxicity and efficacy studies and channel through the most strategic route to lead to clinical trials.
To test the power of combining anti-TICs treatment with other treatment modalities.
Our ultimate goal is to discover new drugs that could, in combination with other drugs, eliminate TICs/ CSCs in cancer.
Our expectations are that research into the biology of TICs/CSCs will have a significant impact on improving the control and elimination of many cancers.
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Computational Biology is at the heart of genomics where we seek to integrate and analyse large and complex data sets in order to derive a more complete systems understanding of biological processes and diseases. This is driven by the development and application of sophisticated computational tools and pipelines for the study of a diverse range of datasets, including targeted The computational tools developed at the GIS are designed for and brought to bear on a diverse array of questions in evolutionary and genomic biology including the following central themes in the CSB programme:
• Can we predict the impact of mutations (substitutions and indels) on protein function? • How do we improve diagnostics for common and rare disorders from genomic information? • What is the role of non-coding sequences in the human genome and how can we identify and characterise disease-causing noncoding polymorphisms? • What is the molecular basis of human-specific traits and how did they evolve? • Can patient-specific driver mutations be predicted and used to personalise cancer therapy? • How do viruses evolve and evade the immune system and can we effectively reconstruct their transmission patterns? • What is the role of microbial communities in the human body in health and disease states?
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With just over a decade of history, the Genome Institute of Singapore already enjoys international recognition as a quality organisation with a global vision that seeks to use genomic sciences to improve public health and public prosperity. The GIS continues to accumulate new discoveries in genomics, and publish
TraNSlaTIONal rESEarCH
high-level research papers in top scientific journals. In recent years, we have expanded our focus to include direct industrial applications for these findings. The critical challenge facing academic centres like our institute is translating basic research and new technology towards clinical utility.
VII
Senior Investigators Alexander LEZHAVA Christopher WONG The Translational Research group promotes the smooth transition from basic research to advances in science and technology, and hence to innovation. Our main focus is on molecular diagnostics, which plays a central role in translational research.
We are able to develop diagnostics for all assay formats and disease areas. Translational research can provide strong evidence that newly discovered biomarkers can be a significant tool for personalised patient care. Our support to the various GIS research groups by assay development, optimisation and validation significantly shortens the distance to commercial applications.
Leveraging on GIS' experience in collaborative interdisciplinary research activities, the Translational Research group facilitates interactions between investigators from different fields such as biotechnology companies, pharmacology companies and hospitals.
The GIS is equipped with the most advanced technology platforms necessary for research and development in genomics, and application of genomic techniques to biological and medical questions. These technologies, such as the Next Generation Sequencing platforms, are accessible to members of the research community. Additionally, in order to adhere to industrial standards, our newly designed and constructed molecular diagnostics lab follows regulatory obligations and compliances.
Our main focus is on molecular diagnostics, which plays a central role in translational research
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A CENTRE FOR GENOMIC DISCOVERY 33 32 platfOrm techNOlOgIeS nexT GenerATiOn SequencinG pLATFOrm Established a decade ago, the GIS Next Generation Sequencing Platform has evolved to become the largest and most productive academic sequencing facility in Singapore. GIS' team of scientists also developed the first protein-mediated interactome protocol, ChIA-PET.
As an endpoint service to a wide range of applications that answer different biological questions, the sequencing platform is critical to the ability to generate data from whole genome sequencing to RNA-sequencing, ChIP-sequencing, exome sequencing and more. With a fleet of Illumina HiSeq and PacBio sequencers, the platform generates massive amounts of data -up to 35 TeraBytes or 40 Gigabases per year. These include 200 million reads of up to 250bp per flowcell, in as short as a two-day turnaround.
This state-of the-art sequencing platform is constantly updating itself with the newest technologies, to maintain its top spot as a sequencing service in Singapore. Not only does the platform look to produce reliable sequencing data in a high throughput manner, it is also expanding its capabilities with new machines to produce longer reads and allow miniaturised sample preparations. Besides housing the newest and most capable sequencers, the sequencing group is also moving towards automating the process with a Biomek FX liquid handler, which will further increase its throughput and efficiency. We aspire to provide high quality sequencing support for the research community in Singapore and beyond.
GenOTypinG pLATFOrm
High throughput, next generation genomic technologies are revolutionising the manner in which research in the field of human heredity is being carried out. As a national institute for genetic and genomic research, sustaining capability and high-level expertise in these technologies is a key strategic priority of the GIS in maintaining its position as one of the leading research institutes in the field.
Being the national flagship institute for genomic research in Singapore, we specialise in a very broad selection of array technology from Illumina and Affymetrix to empower our discovery efforts into the underlying genetic causes of human diseases (both common and rare). We also undertake focused genotyping using the Sequenom and Taqman systems for validation purposes. With dedicated automation and quality control pipelines, we support a wide range of experimental protocols for human genetic research.
We aim to bring together genomics and analysis services to support practising clinicians and scientists from both Singapore and abroad wanting to leverage on the latest technologies in genomics for their research. We collaborate with the GIS multidisciplinary research teams in human genetics, cancer biology and stratified oncology, stem cells, and with researchers across America, Asia and Europe.
hiGh ThrOuGhpuT ceLLuLAr BiOLOGy pLATFOrm High Throughput Screening (HTS) has transformed the way biomedical research is performed by employing laboratory automation and robotics, enabling the functional interrogation of the entire genome and identification of therapeutic drug candidates in a much shorter timeframe than earlier. The application of HTS will ultimately enable the practice of targeted treatments, a first step towards personalised medicine. any genome for a myriad of medical and industrial applications.
Manager
The genome engineering platform (GEP) at the Genome Institute of Singapore is part of a larger crossorganisational research effort on synthetic biology and has the capabilities to responsibly modify the human and mouse genomes for different research purposes. Our work encompasses the generation of genetically altered mice, such as knockouts and knockins, tetraploid complementation assays, teratoma assays, generation and characterisation of induced pluripotent stem cells (iPSCs), and genome editing. We leverage on transcription activator-like effector nucleases (TALENs) and the CRISPRCas system to delete genes and to make precise changes to the genome, so as to gain functional insights into different classes of genes. We collaborate closely with research groups within GIS, other institutes in Singapore especially the universities, and overseas research laboratories.
SinGLe ceLL GenOmicS pLATFOrm
The GIS-Fluidigm Single-Cell Omics Centre (SCOC) is a laboratory located within the Institute dedicated to accelerating the understanding of how individual cells work, and how diagnosis and treatment might be enhanced through insight derived from single cells. The Centre is a collaboration between the Genome Institute of Singapore and Fluidigm Corporation, an industry leader in single-cell genomics. 
GIS FEllOW PrOGrammES
up and run their research projects as a GIS Fellow or GIS Clinician Scientist (CS) Fellow. They will receive mentoring from the faculty they interact with and will be hosted in a laboratory of their choice. They will be given financial support, space and resources in a nurturing environment with access to state-of-the-art research facilities.
Candidates for these programmes should show exceptional promise to develop into world class researchers and their work is expected to further strengthen the key strategic research areas of the GIS. For further information on these programmes, visit the GIS website or email FellowsRecruit@gis.a-star.edu.sg. The GIS attracts highly-motivated postdoctoral researchers from Asia and around the world. Our well-equipped laboratories and collaborative culture offer ideal postdoctoral training for individuals engaged in cutting-edge research at the interface of molecular biology and biochemistry, genomic technology, and scientific computing. Our
POST-DOCTOral PrOGrammES
postdocs work in diverse fields, from cancer biology to stem cell genomics, infectious diseases to population genetics. Postdocs receive competitive salaries and are encouraged to attend international conferences to stay current in their fields of expertise. Interested applicants should visit our web site and apply directly to laboratories of interest.
GraDuaTE PrOGrammES
The GIS welcomes PhD students who are eager to apply modern genomic technologies to problems that lie at the intersection of basic biology and its applications to medicine. The collaborative research environment at GIS is conducive to the training of modern biologists, who increasingly require access to technologies and expertise that lie beyond the realm of a single laboratory.
aTTaCHmENT PrOGrammES
The GIS welcomes applications from university and polytechnic students for our research attachment programme. Students who do attachments at GIS have the opportunity to participate in exciting, modern biological research alongside our scientific staff. In order to have The GIS and its parent organisation, A*STAR, are not universities and cannot offer PhD degrees directly. However, strong links have been established between the GIS and graduate programmes within Singapore to provide PhD students the opportunity to engage in projects at the GIS. Most of our PhD students are enrolled in the graduate programmes of either the National University of Singapore (NUS) or Nanyang Technological University a meaningful research experience, we encourage an attachment duration of at least 12 weeks fulltime (or the equivalent in a part-time attachment). Experience at the GIS has led to several of our attachment students moving on into graduate programmes.
(NTU). In addition, we have a number of international students working towards their PhD at the GIS through partnership programmes between A*STAR and affiliated universities. 
GIS PARTNERSHIP PROGRAMME
As a national fl agship programme for Genomics, GIS has a global vision that seeks to use genomic sciences to improve public health and public prosperity.
To enrich its research programmes and to build a broader national framework for the genomic sciences, the institute launched the GIS partnership programme in 2013. The programme consists of Associate Faculty who bring complementary research strengths to the core faculty of the GIS and help to build up new areas of research. Through a close partnership between the core and associate faculty, this collective group synergises to direct and expand the GIS science portfolios. The associate faculty members are closely engaged in the scientifi c agendas of the GIS, enhance the GIS Translational and Clinical Research (TCR) profi le and expand the GIS collaborative network. In his current studies he is pinpointing the cross-talk between immune cells and insulinproducing ß-cells and the impact of a gene and environmental interplay in the development of metabolic diseases in humans.
Professor
Professor Stuart COOK is Director at the National Heart Research Institute Singapore, Senior Consultant at the National Heart Centre Singapore, Professor of Clinical and Molecular Cardiology at Duke-NUS, and Professor of Clinical and Molecular Cardiology at Imperial College. He heads a cross-disciplinary research team, anchored in human genetic discoveries, with the overarching goal of identifying new genes and pathways for heart disease to reveal new biology and therapeutic targets. Prof Cook's research focus is on genetic basis of cardiovascular disease, disease mechanisms, CMR, novel diagnostics, therapeutic target development, ICCs and heart failure.
